Prevalence of mental disorders in South Asia: A systematic review of reviews Authors: Aishwarya L. Vidyasagaran, David McDaid, Mehreen R. Faisal, Muhammad Nasir, Krishna P. Muliyala, Sreekanth Thekkumkara, Judy Wright, Rumana Huque, Saumit Benkalkar, Najma Siddiqi, Aishwarya Lakshmi Vidyasagaran, Aishwarya Lakshmi Vidyasagaran, Aishwarya Lakshmi Vidyasagaran Published: 2023 ABSTRACT Mental disorders are increasing in South Asia (SA), but their epidemiological burden is under-researched. We carried out a systematic umbrella review to estimate the prevalence of mental disorders and intentional self-harm in the region. Multiple databases were searched and systematic reviews reporting the prevalence of at least one mental disorder from countries in SA were included. Review data were narratively synthesised; primary studies of common mental disorders (CMDs) among adults were identified from a selected subset of reviews and pooled. We included 124 reviews. The majority (n = 65) reported on mood disorders, followed by anxiety disorders (n = 45). High prevalence of mental disorders and intentional self-harm was found in general adult and vulnerable populations. Two reviews met our pre-defined criteria for identifying primary studies of CMDs. Meta-analysis of 25 primary studies showed a pooled prevalence of 16.0% (95% CI = 11.0–22.0%, I 2 = 99.9%) for depression, 12.0% (5.0–21.0%, I 2 = 99.9%) for anxiety, and 14.0% (10.0–19.0, I 2 = 99.9%) for both among the general adult population; pooled estimates varied by country and assessment tool used. Overall, reviews suggest high prevalence for mental disorders in SA, but evidence is limited on conditions other than CMDs. Impact statement Our umbrella review provides the most comprehensive estimates for the prevalence of mental disorders and intentional self-harm in South Asia (SA) and highlights that large proportions of the population in the region (both general-adult and specific vulnerable groups) are affected by these adverse health conditions. Evidence is critically lacking beyond common mental disorders on several conditions including schizophrenia and psychotic disorders, behavioural syndromes, personality disorders and intellectual disabilities. Although limited by heterogeneity and methodological quality of included studies, our review findings show an urgent need for countries in SA to formulate and implement clinical and policy measures for the prevention and early treatment of mental disorders and intentional self-harm. The pooled prevalence estimated for depression and anxiety in the general-adult population could serve as a reference for policymakers to take necessary action for curbing the growing burden of mental disorders in SA. Introduction Mental disorders are recognised to be increasing globally, and contribute to a growing health, social and economic burden (World Health Organization, 2021). From 1990 to 2019, they have gone from the 13th to the 7th leading cause of disease burden in the world, with the number of disability-adjusted life-years (DALYs) due to mental disorders increasing from 80.8 million to 125.3 million; they also remain the second largest contributor to years lived with disability (GBD Mental Disorders Collaborators, 2022). Intentional self-harm accounts for a further 34.1 million DALYs, with their burden being greatest in low- and middle-income countries (Knipe et al., 2022). In South Asia (SA) (Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka) (The World Bank, 2019), rapid demographic and lifestyle changes are said to be associated with an exponential rise in mental and substance-use disorders, which health systems and services are unable to adequately meet (World Health Organization, 2016b; Ambekar et al., 2019). This has resulted in a considerable mental health treatment gap, with more than 75% of people affected in many countries not having access to the treatment they need (World Health Organization, 2016b; Gautham et al., 2020). Further, mental disorders have not been a policy priority among countries in the region, and their epidemiological and psychosocial burdens have been under-researched (Shidhaye et al., 2015). To address these issues and to improve the knowledge base for better planning and decision-making, an overall evaluation of the prevalence of mental disorders and intentional self-harm among countries in SA is needed. Hossain et al. (2020) published an umbrella review, stating its advantages over a review of primary studies for understanding the population-level burden of mental disorders within the SA region. However, their inclusion criteria were limited to reviews solely conducted in SA (i.e., they excluded broader reviews, even if those reviews included some South Asian studies). We considered that expanding the scope of our umbrella review to identify all systematically conducted reviews, so long as they included evidence from at least one country in SA (whilst limiting our synthesis to South Asian studies), would provide a more complete picture of the prevalence of mental disorders and intentional self-harm in the region. In addition, a meta-analysis to provide an updated pooled estimate for the prevalence of mental disorders in the general adult population in SA would complement the overview provided by the umbrella review. Methods The review was registered with PROSPERO (CRD42021282957) (McDaid et al., 2021). We followed the Joanna Briggs Institute (JBI) method for conducting the review (Aromataris et al., 2015) and the PRISMA guidelines for reporting (Page et al., 2021; Supplementary Appendix 1). Search strategy We searched multiple electronic databases and research repositories, covering published and grey literature, on 29 September 2021 (Supplementary Appendix 2). Our searches included index terms, synonyms, and alternative phrases to cover mental disorders, South Asian countries, prevalence or epidemiology, and review types. We used the search strategies for ‘prevalence’ and ‘South Asia’ from Uphoff et al. (2019), and for ‘mental disorders’ from Mishu et al. (2021), adapting them to include all ICD-10 categories of mental disorders and intentional self-harm (World Health Organization, 2016a; Supplementary Appendix 3). Searches were developed by an information specialist (JW) and peer-reviewed by a second, using the PRESS checklist (McGowan et al., 2016). There were no limits for language or publication date. We also screened reference lists and forward citations of included studies. In addition, PROSPERO records were checked for any relevant ongoing or completed reviews. Retrieved records were de-duplicated in EndNote semi-automatically, using specified guidance (AUHE Information Specialists, 2016) and uploaded to COVIDENCE (www.covidence.org) for further evaluation. Inclusion criteria and study selection We included systematic reviews (with or without meta-analyses) that searched two or more databases, and provided keyword and/or search strategies, as per the quality criteria of the AMSTAR2 checklist (Shea et al., 2017). Reviews reporting the prevalence or incidence of mental disorders in one or more countries in the World Bank-defined SA region were eligible. This included reviews that had data from countries beyond SA, but where we could extract the SA data on their own. All populations and settings were eligible, except studies of international military forces based in SA. Reviews on any mental, behavioural, and neurodevelopmental disorders (ICD-10, F-codes), or on suicide and intentional self-harm (ICD-10, X60-X84 codes) were eligible (Supplementary Appendix 4). Two authors independently evaluated all records at title and abstract and full-text screening stages. Discrepancies in screening were addressed through discussion with a third author. Data extraction and synthesis A pre-piloted data extraction tool was uploaded to COVIDENCE. Two authors independently extracted data and performed quality appraisals for 10% of included reviews, with good agreement; discrepancies were identified and resolved through consensus. All remaining extractions were performed by a single author and checked by a second. Extraction items included objective and type of review, year of publication, name and timeframe of databases, originating countries of primary studies, sample size and characteristics, as well as reported prevalence or incidence of mental disorders. We used the AMSTAR2 tool for evaluating the methodological quality of included reviews (Shea et al., 2017). Narrative synthesis was conducted according to the type of review (with or without meta-analysis) and mental disorders (ICD-10 categories), using tables and figures. For the reviews that went beyond SA, we only considered the pooled/range of estimates from the subgroup of studies that were relevant to the SA region. Next, we focused on the reviews with meta-analyses to summarise results for pooled prevalence of mental disorders in SA. Finally, to estimate prevalence for the common mental disorders (CMDs), depression and anxiety, we obtained data from primary studies in the included reviews. We limited this step to reviews with a pre-registered protocol (as a quality indicator), and those reporting on CMDs in the general adult population, given these conditions, which comprise the great majority of mental disorders, were the focus of the bulk of included reviews. Additional primary studies reporting CMD prevalence in SA were identified through forward citation screening of included reviews, to capture more recent studies. Data extraction from primary studies was again performed by a single author and checked by a second on the following items: country, state or province of the study population, sample characteristics and sample size, and prevalence or incidence for each mental disorder. For quality assessment, we used the JBI Critical Appraisal Checklist for prevalence studies (Munn et al., 2014), but did not exclude ones at high risk of bias from further analysis. We created a ‘summary of findings’ table for primary studies and carried out meta-analyses using Stata (2007), Version 17.0 to produce a pooled estimate of prevalence for depression and anxiety among the general population in SA. Heterogeneity was assessed using I 2 statistics, and subgroup analyses based on country and outcome ascertainment tools were conducted to explore the sources. Evidence of publication bias was assessed using funnel plots and Egger’s test. Results Our searches yielded 1,048 records, with 770 remaining after deduplication (Figure 1). Following title and abstract screening, 548 records were excluded, and all but one of the remaining 222 papers were obtained. Full-text screening resulted in the exclusion of 94 records (see Figure 1 and Supplementary Appendix 5 for details). 124 reviews (127 records) met our eligibility criteria and were included in the narrative synthesis. Three reports covering one review were merged (Barua et al., 2010; Barua et al., 2011a, 2011b); for another review, we merged and extracted data from both the original and updated reports (Oram et al., 2012; Ottisova et al., 2016).Figure 1.PRISMA flow chart for included reviews. PRISMA flow chart for included reviews. For the meta-analyses of primary studies, we found only two reviews with pre-registered protocols, which reported on the prevalence of CMDs in the general adult population (Naveed et al., 2020; Zuberi et al., 2021). These provided 22 primary studies. Three additional studies were identified through forward citation screening of included reviews, resulting in 25 distinct primary studies for our meta-analyses (14 depression-only, three anxiety-only, and eight both) (see Supplementary Appendix 6 for flow chart of primary studies). Characteristics of reviews included in the review of reviews Table 1 provides the summary characteristics of all included reviews. Twenty-five reviews had conducted meta-analyses providing pooled estimates for mental disorders in SA. A further 99 reviews did not provide pooled estimates, either because no meta-analysis was conducted (n = 61), no pooled values limited to SA countries were presented (n = 37), or pooled prevalence was not estimated (n = 1).Table 1.Summary characteristics of included reviewsReferenceSouth Asian countries represented in the review (number of primary studies), sample sizePopulationMental disorder(s) and Prevalence/other measure of burden reportedAMSTAR-2 gradingSystematic reviews with meta-analysis (n = 25); reporting pooled prevalence (95% CI) unless otherwise specifiedBarua et al. (2010, 2011a, 2011b)India (6); n = 2,499Older peopleDepression 21.9% (11.6–31.1)Critically lowSteel et al. (2014)Afghanistan (1), Bangladesh (1), India (7), Pakistan (3); n = 17,524General adult populationCMD 19.8% (10.3–34.7)Critically lowCho et al. (2016)India (2), Pakistan (1), Sri Lanka (1); n = 327People with suicidal behaviourAny mental disorder among fatal suicide 90.4% (71.8–97.2)LowRanjan and Asthana (2017)Afghanistan (1), Bangladesh (5), Bhutan (1), India (20), Nepal (3), Pakistan (3), Sri Lanka (1); n = 158,555General adult populationAny mental disorder (rate per 1000) 122.0 (8.0–252.0)Critically lowUpadhyay et al. (2017)India (38); n = 20,043Postpartum womenDepression 22.0% (19.0–25.0)LowHussain et al. (2018)India (37); n = 10,270People with type 2 diabetesDepression 38.0% (31.0–45.0)ModerateChauhan et al. (2019)India (4); n = 130,599ChildrenASD 0.1% (0.0–0.2)LowHendrickson et al. (2019)India (22); n = 5,122Adults with AUDMood disorder 18.0% (5.6–45.1), Anxiety disorder 2.4% (0.9–5.8)LowMahendran et al. (2019)Bangladesh (3), India (12), Maldives (1), Nepal (1), Pakistan (14), Sri Lanka (2); n = 13,087Pregnant womenDepression 24.3% (19.0–30.5)ModeratePilania et al. (2019)India (51); n = 22,005Older peopleDepression 34.4% (29.3–39.7)HighPrabhu et al. (2019)Bangladesh (1), India (12), Maldives (1), Nepal (5), Pakistan (9); n = 15,345Postnatal womenDepression 26.0% (21.0–30.0)Critically lowUphoff et al. (2019)Bangladesh (5), India (60), Pakistan (30), Multi-country (1); n = NRAdults with NCDDepression 41.0% (37.0–44.0), Anxiety 29.0% (22.0–36.0)ModerateGanesan et al. (2020)India (10); n = 6,513Children and adolescentsSuicide attempt past-year 0.6% (0.0–1.8), lifetime 17.1% (5.0–35.4)LowKhan et al. (2020)Pakistan (26); n = 7,652University studentsDepression 42.7% (34.8–50.9)ModerateNaveed et al. (2020) a Bangladesh (8), India (81), Nepal (20), Pakistan (33), Sri Lanka (12), Multi-country (6); n = NR for all studies, range: 250 to 863,657Adults – general, students, older peopleCMD 28.4% (13.9–49.3), Alcohol abuse 12.9% (8.8–18.6), Opiates misuse 0.8% (0.2–2.5), Drug abuse 2.5% (0.1–32.1), Depression 26.4% (23.6–29.4), Bipolar 0.6% (0.3–1.0), Anxiety 25.8% (19.4–33.5), Panic disorder 1.3% (0.5–3.4), Phobias 1.8% (0.4–7.1), OCD 1.6% (0.4–5.5), PTSD 17.2% (11.0–25.9), Suicidal behaviour 6.4% (3.1–12.4)ModerateAbraham et al. (2021)Pakistan (15); n = 2,890HCWsDepression 31.7% (18.7–48.3)HighAssariparambil et al. (2021)Bangladesh (7), India (89), Nepal (12), Pakistan (6), Sri Lanka (6); n = 65,060Older peopleDepression 42.0% (38.0–46.0)LowAtif et al. (2021)Pakistan (43); n = 17,544Perinatal womenDepression antenatal 37.0% (30.0–44.0), postnatal 30.0% (25.0–36.0)LowChoudhary et al. (2021)India (20); n = 86,312Older peopleDementia 2.0% (2.0–3.0)Critically lowHossain et al. (2021)Bangladesh (7), India (19), Nepal (3), Pakistan (5), Sri Lanka (1); n = 41,402General population and HCWs, COVID-19Depression 34.1% (28.9–39.4), Anxiety 41.3% (34.7–48.1)LowHosseinnejad et al. (2021)Pakistan (6); n = 3,403General population, after earthquakesPTSD 49.2% (39.4–59.0)LowKalra et al. (2021)India (27); n = 7,880Antenatal womenCMD 21.9% (17.5–26.3)ModeratePatra et al. (2021)India (15); n = 1,617Stroke survivorsDepression 55.0% (43.0–65.0)LowYadav et al. (2021)India (10); n = 2,362Peri-menopausal womenDepression 42.5% (28.7–57.5)HighZuberi et al. (2021) a Afghanistan (2), Pakistan (5); n = 19,314General adult populationAfghanistan: SUD 0.0% (0.0–1.0), Depressive disorder 33.0% (7.0–75.0), Bipolar 0.0% (0.0–3.0), Anxiety disorder 25.0% (6.0–62.0), OCD 1.0% (0.0–5.0), Panic disorder 0.4% (0.1–2.0) PTSD 35.0% (4.0–87.0); Pakistan: SUD 32.0% (6.0–78.0), Depressive disorder 10.0% (4.0–25.0), Anxiety disorder 4.0% (0.0–27.0)ModerateSystematic reviews with no pooled estimates (n = 99), reporting prevalence/prevalence range unless otherwise specifiedMirza and Jenkins (2004)Pakistan (20); n = 9,170 for 17 relevant studiesGeneral adult populationCMD 33.6%Critically lowMills et al. (2005)India (5); n = 410Tibetan refugee populationMDD 11.5–57.0%, Anxiety 25.0–77.0%, PTSD 11.0–23.0%LowCollins et al. (2006)India (7), Nepal (1); n = 281People with HIV/AIDSAny mental disorder PWA 75.0% and HIVP 47.6%, Alcohol dependency 44.4%, Psychosis 5.0%, Depression 3.0–47.0%, Anxiety 25.0–36.0%, Adjustment disorder 27.8%, Suicidal intention/attempt 14.0%LowLopes et al. (2007)India (2); n = 2,603Older peopleDementia 1.3–3.1%Critically lowMills et al. (2008)Nepal (6); n = 4,712Bhutanese refugee populationDepression 2.0%, Anxiety 4.0%, Phobia 18.5%, Dissociative disorder 8.0%, PTSD 25.0%, Somatoform pain 31.0%Critically lowKlainin and Arthur (2009)India (3), Nepal (1), Pakistan (3); n = 2,072Postpartum womenDepression 4.9–56.0%Critically lowMath and Srinivasaraju (2010)India (16); n = 72,202General adult populationAny disorder (rate per 1000) 9.5–102.0Critically lowDas and Leibowitz (2011)India (NR); n = NRPeople with HIV/AIDSDepression 33.0–70.0%, Anxiety 25.0–36.0%, Adjustment disorder 27.8%, Persistent suicidal intent/attempt 14.0%Critically lowMaulik et al. (2011)Bangladesh (2), India (1), Pakistan (2), Multi-country (1); n = 6,09,731General populationIntellectual disability (rate per 1000) 0.9–156.0LowFisher et al. (2012)Bangladesh (4), India (4), Nepal (2), Pakistan (4); n = 5,126Perinatal womenCMD antenatal 11.5–33.0% and postnatal 9.0–59.4%Critically low Hawton et al. (2013)India (5); n = 649Persons with self-harmDepressive disorder 53.0–89.0%Critically lowJones and Coast (2013)Bangladesh (1), India (3), Nepal (1), Pakistan (3); n = 2,479Postpartum womenDepression 4.9–35.6%LowNadkarni et al. (2013)India (31); n = NR for all studies; range: 100 to 7,554Over 50 yearsAUD 1.1–70.0%Critically lowNewman (2013)Bangladesh (61); n = 12,021 for 16 relevant studiesGeneral, 15 years and olderDepression 6.6–97.0%Critically lowRajapakse et al. (2013)Sri Lanka (23); n = 74,482General or clinical populationIntentional self-poisoning (rate per 100,000) 21.5–224.0LowUdina et al. (2013)India (11), Sri Lanka (1); n = 799Adult malesDhat syndrome ~7% of patients seen at sexual health clinics; Depression 24.0–66.0%, Anxiety 13.0–37.0%Critically lowBeckwith et al. (2014)India (1), Pakistan (1); n = 16,318Mental health outpatientPersonality disorder 1.0–60.0%Critically lowde Bernier et al. (2014)India (4); n = 5,616General or clinical, adultsPersonality disorders 1.3–52.0%Critically lowFuhr et al. (2014)India (7), Nepal (1), Pakistan (1), Sri Lanka (2); n = NRPerinatal womenInjury 1.1–17.9%, Suicide 1.0–10.7%ModerateHossain et al. (2014)Bangladesh (32); n = 25,767General or clinical populationAny mental disorders 6.5–31.4%Critically lowJordans et al. (2014)India (45), Bangladesh (26), Sri Lanka (18), Nepal (12), Pakistan (11), Afghanistan (1), Multi-country (1); n = NRGeneral or clinical populationSuicide (incidence per 100,000) 0.43–331.0Moderate Medlow et al. (2014)India (1); n = 150Homeless adolescentsDepression 8.0%Critically low Mendenhall et al. (2014)Bangladesh (3), India (8), Pakistan (3); n = NRPeople with type 2 diabetesDepression 14.7–84.0%Critically lowPearson et al. (2014)Sri Lanka (149); n = NRGeneral or clinical populationSuicide (rate per 100,000, as figure) ~25.0LowRane and Nadkarni (2014)India (36); n = NRGeneral or clinical populationSuicide (rate per 100,000) 82.0–95.0Critically lowAggarwal and Berk (2015)India (27); n = 36,838AdolescentsDepression 0.5–60.0%, GAD 13.0%, Social anxiety disorder 12.8%, PTSD 29.0%, Behavioural problems 1.8–24.7%, Suicidal behaviour 3.9–25.4%Critically low Malakouti et al. (2015)Pakistan (2); n = 2,663General populationSuicide (rate per 100,000) 0.6–1.1Critically lowNorhayati et al. (2015)Bangladesh (3), India (2), Nepal (2), Pakistan (2); n = 2,545Postpartum womenDepression 3.1–59.4%Critically lowEvagorou et al. (2016)India (2), Nepal (1), Pakistan (1); n = 826Postpartum womenDepression 4.9–63.0%Critically lowMcKenzie et al. (2016)India (1); n = 70,302General populationIntellectual disability (as figure) 1.0–1.2%LowOttisova et al. (2016)Nepal (1); n = 164Victims of human traffickingDepression 86.0%, Anxiety 90.2%, PTSD 13.4%ModerateSahu et al. (2016)India (12); n = 547AmputeesDepression 10.4–63.0%, GAD 3.4–10.0%, PTSD 3.3–56.3%Critically low Tanzil Jamali (2016)Pakistan (8); n = NRChildren and adolescentsLearning disability 24.8%, Emotional or behavioural disorders 34.0%Critically low Aggarwal et al. (2017)India (2); n = 1,67512–25 year oldsNon-suicidal self-harm 31.2%, Suicidal behaviour 6.1%, Suicide attempt 3.5%Critically low Ahmed et al. (2017)Bangladesh (1), India (12), Sri Lanka (3); n = 3,024People with suicidal behaviourDepression among those who died by suicide 6.9–37.1%, attempted 20.7–59.7%LowDennis et al. (2017)Bangladesh (2); n = 1,394Perinatal womenAnxiety 38.3%, Trait anxiety 29.4%LowHossain et al. (2017)Bangladesh (3), India (2), Sri Lanka (1); n = 41,620Children and adolescentsASD 0.1–1.1%Critically lowKuppili et al. (2017)India (73); n = 16,073Children and adolescentsADHD 4.7–29.2%Critically low Naskar et al. (2017)India (41); n = 34,119People with type 1&2 diabetesDepression 2.0–84.0%Critically lowSalmanian et al. (2017)Afghanistan (1); n = 1,011Children and adolescentsConduct disorder 4.8%LowSingh and Balhara (2017)India (52); n = NRPeople with cannabis use and psychiatric disordersHigh frequency of psychiatric symptoms with SUDs, preponderance of cannabis-associated psychotic & affective disordersCritically low Woody et al. (2017)India (3), Nepal (1), Sri Lanka (1); n = NRPerinatal womenDepression NR for countries in SACritically lowYatan Pal Singh et al. (2017)India (13), Nepal (3); n = 51,008General or clinical populationAUD 3.9–100%, Depression 2.7–94.3%Critically lowHalim et al. (2018)Bangladesh (3), India (2), Nepal (2), Pakistan (3); n = 4,546Perinatal womenDepression antenatal 18–33% and postnatal 5–36%, Antenatal anxiety 29%, CMD 16–42%, Suicide attempts 2–5%Critically lowHunt et al. (2018)India (1), Sri Lanka (1); n = 412People with psychosisAUD 3.0–11.0%, CUD 20.0%LowJha et al. (2018)Bangladesh (1), India (4), Pakistan (2), Sri Lanka (1); n = 3,323Antenatal womenDepression 1.9–65.0%, Anxiety 26.0–49.0%Low Morina et al. (2018)Nepal (2), Sri Lanka (2); n = 2,950Refugee and IDPDepression 22.0–80.0%, MDD 5.0–8.0%, Anxiety 33.0–81.0%, PTSD 3.0–53.0%Critically lowMorina et al. (2018)Afghanistan (1), India (1), Sri Lanka (1); n = 18,886Civilian war survivors in area of conflictMajor depression 26.0–37.0%, PTSD 28.0–34.0%ModerateShekhani et al. (2018)Pakistan (110); n = NR for 2 relevant studiesGeneral or clinical populationSuicide (incidence per 100,000) 0.43–2.86Critically lowShorey et al. (2018)India (1), Nepal (1), Pakistan (3); n = 1,329Postpartum womenDepression 5.0–62.0%ModerateThapa et al. (2018)Nepal (32); n = 4,152Older peopleDepressive disorders 4.4–53.2%, Anxiety 21.7–32.3%Critically low Arafat (2019)Bangladesh (18); n = 14,942 for 3 relevant studiesGeneral populationSuicide (rate per 100,000) 30.0–128.8Critically lowBhagavathula et al. (2019)India (17), Pakistan (4); n = 4,441People with hair dye poisoningSuicide intent 75.0–99.9%Critically low Gilmoor et al. (2019)India (56); n = 38,932General or clinical populationPTSD 0.1–89.0%Critically lowKnipe et al. (2019)Bangladesh (2), India (28), Nepal (2), Pakistan (2), Sri Lanka (5); n = 9,888People with suicidal behaviourAny mental disorder among fatal suicide 48.0–96.0% and attempted 0.0–96.0%HighMytton et al. (2019)Nepal (186); n = NRGeneral or clinical populationSelf-harm NR for countries in SACritically lowSomrongthong et al. (2019)India (8); n = 326 for 1 relevant studyFemale sex workers 10–19 yearsSuicidal attempts 41.0%Critically lowTay et al. (2019)Bangladesh (1); n = 148Rohingya refugee populationDepression 89.0%, PTSD 36.0%Critically lowVaidyanathan et al. (2019)India (39); n = 6,663General or clinical populationProbable ED 4.0–45.4%, ED 1.25%Critically low Abate et al. (2020) a India (3), Pakistan (3); n = 1,312People undergoing surgery with anaesthesiaPreoperative anxiety 24.0–88.0%ModerateAkhtar et al. (2020)India (1), Nepal (2), Pakistan (1), Sri Lanka (1); n = 7,495University studentsDepression 9.3–53.1%Moderate Banerjee et al. (2020)Bangladesh (1), India (11), Pakistan (1); n = 7,936General or clinical, COVID-19Depression 10.5–34.9%, Anxiety 38.2–39.5%Critically lowBlackmore et al. (2020)Nepal (1); n = 574Adult refugeesDepression 1.9%, Anxiety 4.7%, PTSD 26.8%ModerateDevarapalli et al. (2020)India (32); n = NR for all studies; range: 103 to 114,068Tribal populationDepression 8.3%, Anxiety 6.4%, Adjustment disorder 9.0%, Somatoform pain 14.0%, PTSD 9.6%, Alcohol abuse 36.2%, Binge eating 6.4%, Bulimia nervosa 1.4%, Self-harm 11.2%, Suicide 14.2%Critically lowDua and Grover (2020)India (33); n = 13,227Clinical population (liaison psychiatry settings)Delirium 2.8–43.4%, Dementia 0.9–3.8%, SUD 1.8–28.9%, Organic psychosis 0.6–25.5%, Psychotic illness 3.2–33.3%, Depression 1.5–24.4%, Bipolar 2.3–10.4%, Anxiety 1.1–13.1%, Adjustment 0.4–16.0%, Dissociation 0.9–8.3%, Psychosomatic 0.8–7.7%, Psychosexual 0.7%, Personality disorder 0.6–5.3%, Mental retardation 0.6–7.0%, Conduct disorder 0.8%, ADHD 0.4–0.8%, Self-harm 2.7–33.9%Critically lowFekadu Dadi et al. (2020)NR; n = NRAntenatal womenDepression NR for countries in SAModerateGilan et al. (2020)India (1); n = 662General or clinical, COVID-19Hypochondriac fear 37.8%LowHunt et al. (2020)Sri Lanka (1); n = 109People with MDDAUD 21.1%, CUD 1.8%Critically lowJanse Van Rensburg et al. (2020)India (11), Pakistan (3), Sri Lanka (1), Multi-country (1); n = NRPeople with tuberculosisAUD 4.0–58.0%, Depression 8.5–84.0%, Anxiety 2.0–47.2%,Critically lowKalra et al. (2020)Bangladesh (8), India (24), Nepal (3), Pakistan (7); n = 12,650Adults with type 2 diabetesDepression 11.6–67.5%Critically low Karimi et al. (2020)India (1); n = 133People with migraineAnxiety 16.54%LowKhunsa Junaid (2020)India (2); n = 8,484HCWs, COVID-19Depression 34.8%LowLasheras et al. (2020)India (1); n = 250Medical students, COVID-19Anxiety 17.2%LowLiu et al. (2020)Sri Lanka (1); n = 335People with history of deliberate self-harmNon-fatal repetition of self-harm (incidence) 3.0%HighQiu et al. (2020)Bangladesh (1), India (1), Nepal (2); n = 43,401Children and adolescentsASD 0.1–0.3%LowRahele et al. (2020)Pakistan (1), Sri Lanka (1); n = 1,786Perinatal women, COVID-19CMD 14.3%, Depression 19.5%, Anxiety 17.5%Critically lowWinsper et al. (2020)Bangladesh (1); n = 76612–18-year-oldsPersonality disorder 0.5%HighYan et al. (2020)Sri Lanka (1); n = 257Perinatal women, COVID-19Depression 28.0%, Anxiety 26.0%ModerateAl Falasi et al. (2021)India (1); n = 426HCWs, COVID-19PTSD 7.3%LowAl Mamun et al. (2021)Bangladesh (9); n = 18,201General or clinical, COVID-19Suicidal behaviour 6.1%Critically lowAmiri and Behnezhad (2021)Bangladesh (1), India (2), Nepal (1); n = 1,034Postpartum womenSuicide attempt 4.0–18.0%Critically lowDavid Franciole de Oliveira et al. (2021)India (1); n = 100Teachers, COVID-19CMD NR for countries in SALowDong et al. (2021)India (1); n = 50People with COVID-19Depression 24.0%, Anxiety 32.0%ModerateDutta et al. (2021)India (4), Nepal (1), Pakistan (2); n = 1,869HCWs, COVID-19Depression 28.2–72.3%, Anxiety 34.0–85.7%ModerateFellmeth et al. (2021)India (7); n = 1,003Perinatal womenDepression 12.5–18.0%HighGhazanfarpour et al. (2021)Pakistan (1), Sri Lanka (1); n = 1,786Pregnant women, COVID-19Depression 19.5%, Anxiety 14.3–17.5%Critically lowHosen et al. (2021)Bangladesh (24); n = 49,806General or clinical, COVID-19Depression 12.1–82.4%, Anxiety 10.6–81.8%, PTSD/Stress 11.1–85.6%Critically lowJephtha and Jagadeesan (2021)India (1); n = 15,981HCWs, COVID-19CMD NR for countries in SACritically lowKar et al. (2021) a Bangladesh (1) India (5) Pakistan (2); n = NRAdult malesDhat syndrome 64.6%Critically lowLiu et al. (2021)India (1); n = 662General, COVID-19Anxiety 58.5%ModerateMahadevan et al. (2021)Bangladesh (1), India (11), Sri Lanka (1); n = 2,013Stroke survivorsDepression 13.8–100.0%, Anxiety 80.9%ModerateMahmud et al. (2021)Bangladesh (2), India (7), Nepal (1), Pakistan (3); n = 5,422HCWs, COVID-19Depression 37.5–53.6%, Anxiety 41.9–62.2%ModerateMamun (2021)Bangladesh (7); n = 21,534Students, COVID-19Depression 46.9–82.4%, Anxiety 26.6–96.8%Critically lowMohammadi et al. (2021)India (3), Sri Lanka (1); n = 3,757Children and adolescentsConduct disorder 1.0–7.0%HighNecho et al. (2021)India (1); n = 662General adult, COVID-19CMD NR for countries in SALowPanda et al. (2021)Bangladesh (1), India (1); n = 505Children, adolescents and caregivers, COVID-19Anxiety, depression and/or sleep disturbance 57.0–68.0%LowSantabárbara et al. (2021) a Bangladesh (2), India (2); n = 4,092General, COVID-19Anxiety 28.0–43.0%ModerateVanderkruik et al. (2021)Bangladesh (4); n = NRAdolescentsDepression during pregnancy 7.0–14.0% and postpartum 10.4–36.2%ModerateWang et al. (2021)Bangladesh (2); n = NRCollege students, COVID-19Depression 47.0–82.0%, Anxiety 33.0–84.0%Critically lowAbbreviations: ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; AUD, alcohol use disorder; CI, confidence interval; CMD, common mental disorder; CUD, cannabis use disorder; ED, eating disorder; GAD, generalised anxiety disorder; HCW, health care worker; HIVP, HIV positive; IDP, internally displaced population; MDD, major depressive disorder; NCD, non-communicable disease; NR, not reported; OCD, obsessive compulsive disorder; PTSD, post-traumatic stress disorder; PWA, people with AIDS; SA, South Asia; SUD, substance use disorder. aReporting discrepancy noted. Table 1.Summary characteristics of included reviewsReferenceSouth Asian countries represented in the review (number of primary studies), sample sizePopulationMental disorder(s) and Prevalence/other measure of burden reportedAMSTAR-2 gradingSystematic reviews with meta-analysis (n = 25); reporting pooled prevalence (95% CI) unless otherwise specifiedBarua et al. (2010, 2011a, 2011b)India (6); n = 2,499Older peopleDepression 21.9% (11.6–31.1)Critically lowSteel et al. (2014)Afghanistan (1), Bangladesh (1), India (7), Pakistan (3); n = 17,524General adult populationCMD 19.8% (10.3–34.7)Critically lowCho et al. (2016)India (2), Pakistan (1), Sri Lanka (1); n = 327People with suicidal behaviourAny mental disorder among fatal suicide 90.4% (71.8–97.2)LowRanjan and Asthana (2017)Afghanistan (1), Bangladesh (5), Bhutan (1), India (20), Nepal (3), Pakistan (3), Sri Lanka (1); n = 158,555General adult populationAny mental disorder (rate per 1000) 122.0 (8.0–252.0)Critically lowUpadhyay et al. (2017)India (38); n = 20,043Postpartum womenDepression 22.0% (19.0–25.0)LowHussain et al. (2018)India (37); n = 10,270People with type 2 diabetesDepression 38.0% (31.0–45.0)ModerateChauhan et al. (2019)India (4); n = 130,599ChildrenASD 0.1% (0.0–0.2)LowHendrickson et al. (2019)India (22); n = 5,122Adults with AUDMood disorder 18.0% (5.6–45.1), Anxiety disorder 2.4% (0.9–5.8)LowMahendran et al. (2019)Bangladesh (3), India (12), Maldives (1), Nepal (1), Pakistan (14), Sri Lanka (2); n = 13,087Pregnant womenDepression 24.3% (19.0–30.5)ModeratePilania et al. (2019)India (51); n = 22,005Older peopleDepression 34.4% (29.3–39.7)HighPrabhu et al. (2019)Bangladesh (1), India (12), Maldives (1), Nepal (5), Pakistan (9); n = 15,345Postnatal womenDepression 26.0% (21.0–30.0)Critically lowUphoff et al. (2019)Bangladesh (5), India (60), Pakistan (30), Multi-country (1); n = NRAdults with NCDDepression 41.0% (37.0–44.0), Anxiety 29.0% (22.0–36.0)ModerateGanesan et al. (2020)India (10); n = 6,513Children and adolescentsSuicide attempt past-year 0.6% (0.0–1.8), lifetime 17.1% (5.0–35.4)LowKhan et al. (2020)Pakistan (26); n = 7,652University studentsDepression 42.7% (34.8–50.9)ModerateNaveed et al. (2020) a Bangladesh (8), India (81), Nepal (20), Pakistan (33), Sri Lanka (12), Multi-country (6); n = NR for all studies, range: 250 to 863,657Adults – general, students, older peopleCMD 28.4% (13.9–49.3), Alcohol abuse 12.9% (8.8–18.6), Opiates misuse 0.8% (0.2–2.5), Drug abuse 2.5% (0.1–32.1), Depression 26.4% (23.6–29.4), Bipolar 0.6% (0.3–1.0), Anxiety 25.8% (19.4–33.5), Panic disorder 1.3% (0.5–3.4), Phobias 1.8% (0.4–7.1), OCD 1.6% (0.4–5.5), PTSD 17.2% (11.0–25.9), Suicidal behaviour 6.4% (3.1–12.4)ModerateAbraham et al. (2021)Pakistan (15); n = 2,890HCWsDepression 31.7% (18.7–48.3)HighAssariparambil et al. (2021)Bangladesh (7), India (89), Nepal (12), Pakistan (6), Sri Lanka (6); n = 65,060Older peopleDepression 42.0% (38.0–46.0)LowAtif et al. (2021)Pakistan (43); n = 17,544Perinatal womenDepression antenatal 37.0% (30.0–44.0), postnatal 30.0% (25.0–36.0)LowChoudhary et al. (2021)India (20); n = 86,312Older peopleDementia 2.0% (2.0–3.0)Critically lowHossain et al. (2021)Bangladesh (7), India (19), Nepal (3), Pakistan (5), Sri Lanka (1); n = 41,402General population and HCWs, COVID-19Depression 34.1% (28.9–39.4), Anxiety 41.3% (34.7–48.1)LowHosseinnejad et al. (2021)Pakistan (6); n = 3,403General population, after earthquakesPTSD 49.2% (39.4–59.0)LowKalra et al. (2021)India (27); n = 7,880Antenatal womenCMD 21.9% (17.5–26.3)ModeratePatra et al. (2021)India (15); n = 1,617Stroke survivorsDepression 55.0% (43.0–65.0)LowYadav et al. (2021)India (10); n = 2,362Peri-menopausal womenDepression 42.5% (28.7–57.5)HighZuberi et al. (2021) a Afghanistan (2), Pakistan (5); n = 19,314General adult populationAfghanistan: SUD 0.0% (0.0–1.0), Depressive disorder 33.0% (7.0–75.0), Bipolar 0.0% (0.0–3.0), Anxiety disorder 25.0% (6.0–62.0), OCD 1.0% (0.0–5.0), Panic disorder 0.4% (0.1–2.0) PTSD 35.0% (4.0–87.0); Pakistan: SUD 32.0% (6.0–78.0), Depressive disorder 10.0% (4.0–25.0), Anxiety disorder 4.0% (0.0–27.0)ModerateSystematic reviews with no pooled estimates (n = 99), reporting prevalence/prevalence range unless otherwise specifiedMirza and Jenkins (2004)Pakistan (20); n = 9,170 for 17 relevant studiesGeneral adult populationCMD 33.6%Critically lowMills et al. (2005)India (5); n = 410Tibetan refugee populationMDD 11.5–57.0%, Anxiety 25.0–77.0%, PTSD 11.0–23.0%LowCollins et al. (2006)India (7), Nepal (1); n = 281People with HIV/AIDSAny mental disorder PWA 75.0% and HIVP 47.6%, Alcohol dependency 44.4%, Psychosis 5.0%, Depression 3.0–47.0%, Anxiety 25.0–36.0%, Adjustment disorder 27.8%, Suicidal intention/attempt 14.0%LowLopes et al. (2007)India (2); n = 2,603Older peopleDementia 1.3–3.1%Critically lowMills et al. (2008)Nepal (6); n = 4,712Bhutanese refugee populationDepression 2.0%, Anxiety 4.0%, Phobia 18.5%, Dissociative disorder 8.0%, PTSD 25.0%, Somatoform pain 31.0%Critically lowKlainin and Arthur (2009)India (3), Nepal (1), Pakistan (3); n = 2,072Postpartum womenDepression 4.9–56.0%Critically lowMath and Srinivasaraju (2010)India (16); n = 72,202General adult populationAny disorder (rate per 1000) 9.5–102.0Critically lowDas and Leibowitz (2011)India (NR); n = NRPeople with HIV/AIDSDepression 33.0–70.0%, Anxiety 25.0–36.0%, Adjustment disorder 27.8%, Persistent suicidal intent/attempt 14.0%Critically lowMaulik et al. (2011)Bangladesh (2), India (1), Pakistan (2), Multi-country (1); n = 6,09,731General populationIntellectual disability (rate per 1000) 0.9–156.0LowFisher et al. (2012)Bangladesh (4), India (4), Nepal (2), Pakistan (4); n = 5,126Perinatal womenCMD antenatal 11.5–33.0% and postnatal 9.0–59.4%Critically low Hawton et al. (2013)India (5); n = 649Persons with self-harmDepressive disorder 53.0–89.0%Critically lowJones and Coast (2013)Bangladesh (1), India (3), Nepal (1), Pakistan (3); n = 2,479Postpartum womenDepression 4.9–35.6%LowNadkarni et al. (2013)India (31); n = NR for all studies; range: 100 to 7,554Over 50 yearsAUD 1.1–70.0%Critically lowNewman (2013)Bangladesh (61); n = 12,021 for 16 relevant studiesGeneral, 15 years and olderDepression 6.6–97.0%Critically lowRajapakse et al. (2013)Sri Lanka (23); n = 74,482General or clinical populationIntentional self-poisoning (rate per 100,000) 21.5–224.0LowUdina et al. (2013)India (11), Sri Lanka (1); n = 799Adult malesDhat syndrome ~7% of patients seen at sexual health clinics; Depression 24.0–66.0%, Anxiety 13.0–37.0%Critically lowBeckwith et al. (2014)India (1), Pakistan (1); n = 16,318Mental health outpatientPersonality disorder 1.0–60.0%Critically lowde Bernier et al. (2014)India (4); n = 5,616General or clinical, adultsPersonality disorders 1.3–52.0%Critically lowFuhr et al. (2014)India (7), Nepal (1), Pakistan (1), Sri Lanka (2); n = NRPerinatal womenInjury 1.1–17.9%, Suicide 1.0–10.7%ModerateHossain et al. (2014)Bangladesh (32); n = 25,767General or clinical populationAny mental disorders 6.5–31.4%Critically lowJordans et al. (2014)India (45), Bangladesh (26), Sri Lanka (18), Nepal (12), Pakistan (11), Afghanistan (1), Multi-country (1); n = NRGeneral or clinical populationSuicide (incidence per 100,000) 0.43–331.0Moderate Medlow et al. (2014)India (1); n = 150Homeless adolescentsDepression 8.0%Critically low Mendenhall et al. (2014)Bangladesh (3), India (8), Pakistan (3); n = NRPeople with type 2 diabetesDepression 14.7–84.0%Critically lowPearson et al. (2014)Sri Lanka (149); n = NRGeneral or clinical populationSuicide (rate per 100,000, as figure) ~25.0LowRane and Nadkarni (2014)India (36); n = NRGeneral or clinical populationSuicide (rate per 100,000) 82.0–95.0Critically lowAggarwal and Berk (2015)India (27); n = 36,838AdolescentsDepression 0.5–60.0%, GAD 13.0%, Social anxiety disorder 12.8%, PTSD 29.0%, Behavioural problems 1.8–24.7%, Suicidal behaviour 3.9–25.4%Critically low Malakouti et al. (2015)Pakistan (2); n = 2,663General populationSuicide (rate per 100,000) 0.6–1.1Critically lowNorhayati et al. (2015)Bangladesh (3), India (2), Nepal (2), Pakistan (2); n = 2,545Postpartum womenDepression 3.1–59.4%Critically lowEvagorou et al. (2016)India (2), Nepal (1), Pakistan (1); n = 826Postpartum womenDepression 4.9–63.0%Critically lowMcKenzie et al. (2016)India (1); n = 70,302General populationIntellectual disability (as figure) 1.0–1.2%LowOttisova et al. (2016)Nepal (1); n = 164Victims of human traffickingDepression 86.0%, Anxiety 90.2%, PTSD 13.4%ModerateSahu et al. (2016)India (12); n = 547AmputeesDepression 10.4–63.0%, GAD 3.4–10.0%, PTSD 3.3–56.3%Critically low Tanzil Jamali (2016)Pakistan (8); n = NRChildren and adolescentsLearning disability 24.8%, Emotional or behavioural disorders 34.0%Critically low Aggarwal et al. (2017)India (2); n = 1,67512–25 year oldsNon-suicidal self-harm 31.2%, Suicidal behaviour 6.1%, Suicide attempt 3.5%Critically low Ahmed et al. (2017)Bangladesh (1), India (12), Sri Lanka (3); n = 3,024People with suicidal behaviourDepression among those who died by suicide 6.9–37.1%, attempted 20.7–59.7%LowDennis et al. (2017)Bangladesh (2); n = 1,394Perinatal womenAnxiety 38.3%, Trait anxiety 29.4%LowHossain et al. (2017)Bangladesh (3), India (2), Sri Lanka (1); n = 41,620Children and adolescentsASD 0.1–1.1%Critically lowKuppili et al. (2017)India (73); n = 16,073Children and adolescentsADHD 4.7–29.2%Critically low Naskar et al. (2017)India (41); n = 34,119People with type 1&2 diabetesDepression 2.0–84.0%Critically lowSalmanian et al. (2017)Afghanistan (1); n = 1,011Children and adolescentsConduct disorder 4.8%LowSingh and Balhara (2017)India (52); n = NRPeople with cannabis use and psychiatric disordersHigh frequency of psychiatric symptoms with SUDs, preponderance of cannabis-associated psychotic & affective disordersCritically low Woody et al. (2017)India (3), Nepal (1), Sri Lanka (1); n = NRPerinatal womenDepression NR for countries in SACritically lowYatan Pal Singh et al. (2017)India (13), Nepal (3); n = 51,008General or clinical populationAUD 3.9–100%, Depression 2.7–94.3%Critically lowHalim et al. (2018)Bangladesh (3), India (2), Nepal (2), Pakistan (3); n = 4,546Perinatal womenDepression antenatal 18–33% and postnatal 5–36%, Antenatal anxiety 29%, CMD 16–42%, Suicide attempts 2–5%Critically lowHunt et al. (2018)India (1), Sri Lanka (1); n = 412People with psychosisAUD 3.0–11.0%, CUD 20.0%LowJha et al. (2018)Bangladesh (1), India (4), Pakistan (2), Sri Lanka (1); n = 3,323Antenatal womenDepression 1.9–65.0%, Anxiety 26.0–49.0%Low Morina et al. (2018)Nepal (2), Sri Lanka (2); n = 2,950Refugee and IDPDepression 22.0–80.0%, MDD 5.0–8.0%, Anxiety 33.0–81.0%, PTSD 3.0–53.0%Critically lowMorina et al. (2018)Afghanistan (1), India (1), Sri Lanka (1); n = 18,886Civilian war survivors in area of conflictMajor depression 26.0–37.0%, PTSD 28.0–34.0%ModerateShekhani et al. (2018)Pakistan (110); n = NR for 2 relevant studiesGeneral or clinical populationSuicide (incidence per 100,000) 0.43–2.86Critically lowShorey et al. (2018)India (1), Nepal (1), Pakistan (3); n = 1,329Postpartum womenDepression 5.0–62.0%ModerateThapa et al. (2018)Nepal (32); n = 4,152Older peopleDepressive disorders 4.4–53.2%, Anxiety 21.7–32.3%Critically low Arafat (2019)Bangladesh (18); n = 14,942 for 3 relevant studiesGeneral populationSuicide (rate per 100,000) 30.0–128.8Critically lowBhagavathula et al. (2019)India (17), Pakistan (4); n = 4,441People with hair dye poisoningSuicide intent 75.0–99.9%Critically low Gilmoor et al. (2019)India (56); n = 38,932General or clinical populationPTSD 0.1–89.0%Critically lowKnipe et al. (2019)Bangladesh (2), India (28), Nepal (2), Pakistan (2), Sri Lanka (5); n = 9,888People with suicidal behaviourAny mental disorder among fatal suicide 48.0–96.0% and attempted 0.0–96.0%HighMytton et al. (2019)Nepal (186); n = NRGeneral or clinical populationSelf-harm NR for countries in SACritically lowSomrongthong et al. (2019)India (8); n = 326 for 1 relevant studyFemale sex workers 10–19 yearsSuicidal attempts 41.0%Critically lowTay et al. (2019)Bangladesh (1); n = 148Rohingya refugee populationDepression 89.0%, PTSD 36.0%Critically lowVaidyanathan et al. (2019)India (39); n = 6,663General or clinical populationProbable ED 4.0–45.4%, ED 1.25%Critically low Abate et al. (2020) a India (3), Pakistan (3); n = 1,312People undergoing surgery with anaesthesiaPreoperative anxiety 24.0–88.0%ModerateAkhtar et al. (2020)India (1), Nepal (2), Pakistan (1), Sri Lanka (1); n = 7,495University studentsDepression 9.3–53.1%Moderate Banerjee et al. (2020)Bangladesh (1), India (11), Pakistan (1); n = 7,936General or clinical, COVID-19Depression 10.5–34.9%, Anxiety 38.2–39.5%Critically lowBlackmore et al. (2020)Nepal (1); n = 574Adult refugeesDepression 1.9%, Anxiety 4.7%, PTSD 26.8%ModerateDevarapalli et al. (2020)India (32); n = NR for all studies; range: 103 to 114,068Tribal populationDepression 8.3%, Anxiety 6.4%, Adjustment disorder 9.0%, Somatoform pain 14.0%, PTSD 9.6%, Alcohol abuse 36.2%, Binge eating 6.4%, Bulimia nervosa 1.4%, Self-harm 11.2%, Suicide 14.2%Critically lowDua and Grover (2020)India (33); n = 13,227Clinical population (liaison psychiatry settings)Delirium 2.8–43.4%, Dementia 0.9–3.8%, SUD 1.8–28.9%, Organic psychosis 0.6–25.5%, Psychotic illness 3.2–33.3%, Depression 1.5–24.4%, Bipolar 2.3–10.4%, Anxiety 1.1–13.1%, Adjustment 0.4–16.0%, Dissociation 0.9–8.3%, Psychosomatic 0.8–7.7%, Psychosexual 0.7%, Personality disorder 0.6–5.3%, Mental retardation 0.6–7.0%, Conduct disorder 0.8%, ADHD 0.4–0.8%, Self-harm 2.7–33.9%Critically lowFekadu Dadi et al. (2020)NR; n = NRAntenatal womenDepression NR for countries in SAModerateGilan et al. (2020)India (1); n = 662General or clinical, COVID-19Hypochondriac fear 37.8%LowHunt et al. (2020)Sri Lanka (1); n = 109People with MDDAUD 21.1%, CUD 1.8%Critically lowJanse Van Rensburg et al. (2020)India (11), Pakistan (3), Sri Lanka (1), Multi-country (1); n = NRPeople with tuberculosisAUD 4.0–58.0%, Depression 8.5–84.0%, Anxiety 2.0–47.2%,Critically lowKalra et al. (2020)Bangladesh (8), India (24), Nepal (3), Pakistan (7); n = 12,650Adults with type 2 diabetesDepression 11.6–67.5%Critically low Karimi et al. (2020)India (1); n = 133People with migraineAnxiety 16.54%LowKhunsa Junaid (2020)India (2); n = 8,484HCWs, COVID-19Depression 34.8%LowLasheras et al. (2020)India (1); n = 250Medical students, COVID-19Anxiety 17.2%LowLiu et al. (2020)Sri Lanka (1); n = 335People with history of deliberate self-harmNon-fatal repetition of self-harm (incidence) 3.0%HighQiu et al. (2020)Bangladesh (1), India (1), Nepal (2); n = 43,401Children and adolescentsASD 0.1–0.3%LowRahele et al. (2020)Pakistan (1), Sri Lanka (1); n = 1,786Perinatal women, COVID-19CMD 14.3%, Depression 19.5%, Anxiety 17.5%Critically lowWinsper et al. (2020)Bangladesh (1); n = 76612–18-year-oldsPersonality disorder 0.5%HighYan et al. (2020)Sri Lanka (1); n = 257Perinatal women, COVID-19Depression 28.0%, Anxiety 26.0%ModerateAl Falasi et al. (2021)India (1); n = 426HCWs, COVID-19PTSD 7.3%LowAl Mamun et al. (2021)Bangladesh (9); n = 18,201General or clinical, COVID-19Suicidal behaviour 6.1%Critically lowAmiri and Behnezhad (2021)Bangladesh (1), India (2), Nepal (1); n = 1,034Postpartum womenSuicide attempt 4.0–18.0%Critically lowDavid Franciole de Oliveira et al. (2021)India (1); n = 100Teachers, COVID-19CMD NR for countries in SALowDong et al. (2021)India (1); n = 50People with COVID-19Depression 24.0%, Anxiety 32.0%ModerateDutta et al. (2021)India (4), Nepal (1), Pakistan (2); n = 1,869HCWs, COVID-19Depression 28.2–72.3%, Anxiety 34.0–85.7%ModerateFellmeth et al. (2021)India (7); n = 1,003Perinatal womenDepression 12.5–18.0%HighGhazanfarpour et al. (2021)Pakistan (1), Sri Lanka (1); n = 1,786Pregnant women, COVID-19Depression 19.5%, Anxiety 14.3–17.5%Critically lowHosen et al. (2021)Bangladesh (24); n = 49,806General or clinical, COVID-19Depression 12.1–82.4%, Anxiety 10.6–81.8%, PTSD/Stress 11.1–85.6%Critically lowJephtha and Jagadeesan (2021)India (1); n = 15,981HCWs, COVID-19CMD NR for countries in SACritically lowKar et al. (2021) a Bangladesh (1) India (5) Pakistan (2); n = NRAdult malesDhat syndrome 64.6%Critically lowLiu et al. (2021)India (1); n = 662General, COVID-19Anxiety 58.5%ModerateMahadevan et al. (2021)Bangladesh (1), India (11), Sri Lanka (1); n = 2,013Stroke survivorsDepression 13.8–100.0%, Anxiety 80.9%ModerateMahmud et al. (2021)Bangladesh (2), India (7), Nepal (1), Pakistan (3); n = 5,422HCWs, COVID-19Depression 37.5–53.6%, Anxiety 41.9–62.2%ModerateMamun (2021)Bangladesh (7); n = 21,534Students, COVID-19Depression 46.9–82.4%, Anxiety 26.6–96.8%Critically lowMohammadi et al. (2021)India (3), Sri Lanka (1); n = 3,757Children and adolescentsConduct disorder 1.0–7.0%HighNecho et al. (2021)India (1); n = 662General adult, COVID-19CMD NR for countries in SALowPanda et al. (2021)Bangladesh (1), India (1); n = 505Children, adolescents and caregivers, COVID-19Anxiety, depression and/or sleep disturbance 57.0–68.0%LowSantabárbara et al. (2021) a Bangladesh (2), India (2); n = 4,092General, COVID-19Anxiety 28.0–43.0%ModerateVanderkruik et al. (2021)Bangladesh (4); n = NRAdolescentsDepression during pregnancy 7.0–14.0% and postpartum 10.4–36.2%ModerateWang et al. (2021)Bangladesh (2); n = NRCollege students, COVID-19Depression 47.0–82.0%, Anxiety 33.0–84.0%Critically lowAbbreviations: ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; AUD, alcohol use disorder; CI, confidence interval; CMD, common mental disorder; CUD, cannabis use disorder; ED, eating disorder; GAD, generalised anxiety disorder; HCW, health care worker; HIVP, HIV positive; IDP, internally displaced population; MDD, major depressive disorder; NCD, non-communicable disease; NR, not reported; OCD, obsessive compulsive disorder; PTSD, post-traumatic stress disorder; PWA, people with AIDS; SA, South Asia; SUD, substance use disorder. aReporting discrepancy noted. Summary characteristics of included reviews Abbreviations: ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; AUD, alcohol use disorder; CI, confidence interval; CMD, common mental disorder; CUD, cannabis use disorder; ED, eating disorder; GAD, generalised anxiety disorder; HCW, health care worker; HIVP, HIV positive; IDP, internally displaced population; MDD, major depressive disorder; NCD, non-communicable disease; NR, not reported; OCD, obsessive compulsive disorder; PTSD, post-traumatic stress disorder; PWA, people with AIDS; SA, South Asia; SUD, substance use disorder. Reporting discrepancy noted. The earliest review was published in 2004 (Mirza and Jenkins, 2004), with the majority (n = 116) published after 2010. The number of databases searched ranged from two to fourteen, and the majority of reviews presented evidence from India (n = 90). The number of South Asian primary studies ranged from one to 149, and sample size ranged from 109 to 863,657 (not reported in 15 reviews). Reviews covered diverse populations, with participants recruited from a range of clinical and community-based settings. Only ten reviews were rated as ‘high’ quality, while most (61) were rated as ‘critically low’ (details in Supplementary Appendix 7). A total of 65 reviews presented the prevalence of mood (affective) disorders including depressive and bipolar disorders, followed by 45 on anxiety disorders, and 10 on a combination of mood and anxiety disorders, grouped together as CMDs. A further nine reviews reported the prevalence of substance use disorders (SUDs), while others covered a range of other mental disorders: seven on behavioural and emotional disorders with usual onset in childhood and adolescence, including conduct disorder and attention-deficit hyperactivity disorder (ADHD), four on pervasive developmental disorders including autism spectrum disorder (ASD), three each on dementia, schizophrenia and psychotic disorder, personality disorder, and intellectual disabilities, and two on eating disorders. Of these, only one included a meta-analysis providing a pooled estimate of ASD prevalence among children in India. We also found six reviews that reported the prevalence of ‘any mental disorder’ and 23 that reported on suicide and intentional self-harm. Many identified reviews covered mental disorders in specific population subgroups including older people, perinatal women, students, healthcare workers (HCWs), and persons with comorbidities. Twenty-two reviews focused on the impact of COVID-19 on the psychosocial health of various population groups (Supplementary Appendix 8). Summary of pooled prevalence from systematic reviews with meta-analysis We now focus on the 25 reviews with meta-analyses on the prevalence of various mental disorders in SA. Eleven were exclusively of studies conducted in India, four in Pakistan, and the remaining 10 covered multiple countries in the region. The population comprised all adults (including perinatal women and older people, n = 1), general adults (n = 3), adults with specific conditions such as alcohol use disorders (AUD) or non-communicable disease (NCD) (n = 6), women (n = 6), older people (n = 4), children and adolescents (n = 2), HCWs (n = 2), and university students (n = 1). In general, these reviews reported high pooled prevalence of mental disorders among both general-adult (up to 33.0% for depression) (Naveed et al., 2020), and specific population subgroups (up to 55.0% for depression among stroke survivors) (Patra et al., 2021). The pooled prevalence of suicidal behaviours among adults was 6.4% (95% CI = 3.1–12.4) (Naveed et al., 2020), and among children and adolescents was 17.1% (5.0–35.4) (Ganesan et al., 2020), whereas the pooled prevalence of any mental disorder among victims of suicide was 90.4% (71.8–97.2) (Cho et al., 2016). We identified 19 pooled estimates for mood disorders (17 studies), followed by six for anxiety disorders (5 studies), and three for CMDs (Figure 2). The pooled prevalence (range) for depressive disorders in the general population was 10.0% (4.0–25.0) to 33.0% (7.0–75.0). Estimates were generally higher for specific population subgroups, including older people (21.9% (11.6–31.1) to 42.0% (38.0–46.0)), perinatal women (22.0% (19.0–25.0) to 37.0% (30.0–44.0)), peri-menopausal women (42.5% (28.7–57.5)), university students (42.7% (34.8–50.9), HCWs = 31.7% (18.7–48.3) to 34.1% (28.9–39.4)), and adults with comorbidities (18.0% (5.6–45.1) to 55.0% (43.0–65.0)). Similarly, pooled prevalence (range) for anxiety disorders in the general population was 4.0% (0.0–27.0) to 25.8% (19.4–33.5); for adults with comorbidities, it was 2.4% (0.9–5.8) to 29.0% (22.0–36.0), and among all adults and HCWs during the COVID-19 pandemic it was 41.3% (34.7–48.1). Based on reviews covering multiple countries in SA, the pooled prevalence of CMDs in the general adult population alone was estimated to be 19.8% (10.3–34.7) (Steel et al., 2014), whereas it was higher (28.4% (13.9–49.3)) among adult populations that included older people and perinatal women (Naveed et al., 2020). One review from India reported a pooled value of 21.9% (17.5–26.3) for prevalence of CMDs among antenatal women (Kalra et al., 2021).Figure 2.Pooled estimates of CMDs, depression and anxiety from meta-analytic reviews.Note: Two studies (2021 Atif and 2021 Zuberi) provided two relevant estimates each for different population groups; the vertical dotted line denotes a pooled prevalence of 14.0% (drawn to correspond with the Figure 3 forest plot). Pooled estimates of CMDs, depression and anxiety from meta-analytic reviews. Note: Two studies (2021 Atif and 2021 Zuberi) provided two relevant estimates each for different population groups; the vertical dotted line denotes a pooled prevalence of 14.0% (drawn to correspond with the Figure 3 forest plot). We also found one general-adult, population-based estimate for the pooled prevalence of any mental disorder, covering all countries in SA except Maldives and presented as a rate per 1000 (95% CI): 122.0 (8.0–252.0) (Ranjan and Asthana, 2017). In addition, we found two meta-analyses reporting SUDs prevalence of 0.0% (0.0–1.0) to 32.0% (6.0–78.0) (Naveed et al., 2020; Zuberi et al., 2021), one on dementia prevalence (2.0% (2.0–3.0)) (Choudhary et al., 2021) and one on ASD prevalence (0.1% (0.0–0.2)) (Chauhan et al., 2019). These are not presented in Figure 2. Pooled prevalence of depression and anxiety in the general adult population from primary studies We identified 25 primary studies reporting the prevalence of CMDs in the general adult population (Table 2): 16 from India, three from Nepal, one each from Pakistan, Sri Lanka, and Afghanistan, and three large, population-based studies that covered multiple countries in SA. Study quality overall was high. Meta-analyses found a pooled prevalence of 16.0% (95% CI = 11.0–22.0, I 2 = 99.9%) for depression, 12.0% (5.0–21.0, I 2 = 99.9%) for anxiety, and 14.0% (10.0–19.0, I 2 = 99.9%) for depression and anxiety combined (Figure 3).Table 2.Summary characteristics of primary studies included in meta-analysesStudyCountrySettingStudy designSample sizeMental disorder(s) and assessment tools usedQuality scoreKohrt et al. (2009)NepalMixedCross-sectional for prevalence307Depression – Beck Depression Inventory (BDI); Anxiety – Beck Anxiety Inventory (BAI)7Poongothai et al. (2009)IndiaUrbanCross-sectional25,455Depression – Modified Patient Health Questionnaire (PHQ12)9Ball et al. (2010)Sri LankaMixedCross-sectional5,973Depression – Composite International Diagnostic Interview (CIDI)9Deswal and Pawar (2012)IndiaUrbanCross-sectional3,023Depression, Anxiety – CIDI9Axinn et al. (2013)NepalRuralCross-sectional400Depression – CIDI7Firdaus and Ahmad (2014)IndiaUrbanCross-sectional1,326 in 2003; 1,965 in 2013Depression – Centre for Epidemiologic Studies Depression Scale (CES-D)9Jonas et al. (2014)IndiaRuralCross-sectional4,711Depression – CES-D8Rao et al. (2014)IndiaRuralCross-sectional3,033Depression, Anxiety – Mini international neuropsychiatric interview (MINI)9Kausar et al. (2015)PakistanUrbanCross-sectional1,110Depression – DSM-based questionnaire7Mathias et al. (2015)IndiaMixedCross-sectional960Depression – PHQ99Kato (2016)IndiaNRCross-sectional300Depression – PHQ9 and CES-D6Risal et al. (2016)NepalMixedCross-sectional2,100Depression, Anxiety – Hospital Anxiety and Depression Scale (HADS)9Shidhaye et al. (2016)IndiaRuralCross-sectional1,456Depression – PHQ99Stubbs et al. (2016)Bangladesh, India, Nepal, Pakistan, Sri LankaMixedCross-sectional178,867Depression – Based on DSM8Bishwajit et al. (2017)Bangladesh, India, NepalMixedCross-sectional14,133Depression – Self-reported4Chaudhuri et al. (2017)IndiaMixedCross-sectional469Depression – BDI9Housen et al. (2017)IndiaMixedCross-sectional5,428Depression, Anxiety – Hopkins Symptom Checklist (HSCL-25)9Patel et al. (2017)IndiaUrbanCross-sectional605Anxiety – State-Trait Anxiety Inventory (STAI) scale6Sagar et al. (2017)IndiaMixedCross-sectional24,371Anxiety – CIDI9Shidhaye et al. (2017)IndiaMixedCross-sectional3,220Depression – PHQ99Stubbs et al. (2017)Bangladesh, India, Nepal, Pakistan, Sri LankaMixedCross-sectional237,964Anxiety – Self-reported6Kar et al. (2018)IndiaMixedCross-sectional3,508Depression, Anxiety – MINI, version 6.0.09Chavan et al. (2018)IndiaMixedCross-sectional2,895Depression, Anxiety – MINI, version 6.0.09Arvind (2019)IndiaMixedCross-sectional34,802Depression – MINI, version 6.0.09Kovess-Masfety et al. (2021)AfghanistanMixedCross-sectional4,433Depression, Anxiety – CIDI8 Figure 3.Forest plot of primary studies on the prevalence of depression and anxiety in South Asia. Table 2.Summary characteristics of primary studies included in meta-analysesStudyCountrySettingStudy designSample sizeMental disorder(s) and assessment tools usedQuality scoreKohrt et al. (2009)NepalMixedCross-sectional for prevalence307Depression – Beck Depression Inventory (BDI); Anxiety – Beck Anxiety Inventory (BAI)7Poongothai et al. (2009)IndiaUrbanCross-sectional25,455Depression – Modified Patient Health Questionnaire (PHQ12)9Ball et al. (2010)Sri LankaMixedCross-sectional5,973Depression – Composite International Diagnostic Interview (CIDI)9Deswal and Pawar (2012)IndiaUrbanCross-sectional3,023Depression, Anxiety – CIDI9Axinn et al. (2013)NepalRuralCross-sectional400Depression – CIDI7Firdaus and Ahmad (2014)IndiaUrbanCross-sectional1,326 in 2003; 1,965 in 2013Depression – Centre for Epidemiologic Studies Depression Scale (CES-D)9Jonas et al. (2014)IndiaRuralCross-sectional4,711Depression – CES-D8Rao et al. (2014)IndiaRuralCross-sectional3,033Depression, Anxiety – Mini international neuropsychiatric interview (MINI)9Kausar et al. (2015)PakistanUrbanCross-sectional1,110Depression – DSM-based questionnaire7Mathias et al. (2015)IndiaMixedCross-sectional960Depression – PHQ99Kato (2016)IndiaNRCross-sectional300Depression – PHQ9 and CES-D6Risal et al. (2016)NepalMixedCross-sectional2,100Depression, Anxiety – Hospital Anxiety and Depression Scale (HADS)9Shidhaye et al. (2016)IndiaRuralCross-sectional1,456Depression – PHQ99Stubbs et al. (2016)Bangladesh, India, Nepal, Pakistan, Sri LankaMixedCross-sectional178,867Depression – Based on DSM8Bishwajit et al. (2017)Bangladesh, India, NepalMixedCross-sectional14,133Depression – Self-reported4Chaudhuri et al. (2017)IndiaMixedCross-sectional469Depression – BDI9Housen et al. (2017)IndiaMixedCross-sectional5,428Depression, Anxiety – Hopkins Symptom Checklist (HSCL-25)9Patel et al. (2017)IndiaUrbanCross-sectional605Anxiety – State-Trait Anxiety Inventory (STAI) scale6Sagar et al. (2017)IndiaMixedCross-sectional24,371Anxiety – CIDI9Shidhaye et al. (2017)IndiaMixedCross-sectional3,220Depression – PHQ99Stubbs et al. (2017)Bangladesh, India, Nepal, Pakistan, Sri LankaMixedCross-sectional237,964Anxiety – Self-reported6Kar et al. (2018)IndiaMixedCross-sectional3,508Depression, Anxiety – MINI, version 6.0.09Chavan et al. (2018)IndiaMixedCross-sectional2,895Depression, Anxiety – MINI, version 6.0.09Arvind (2019)IndiaMixedCross-sectional34,802Depression – MINI, version 6.0.09Kovess-Masfety et al. (2021)AfghanistanMixedCross-sectional4,433Depression, Anxiety – CIDI8 Summary characteristics of primary studies included in meta-analyses Forest plot of primary studies on the prevalence of depression and anxiety in South Asia. The pooled prevalence (95% CI) of depression varied notably by country, from 5.0% (4.0–6.0) in Afghanistan, 5.0% (5.0–6.0) in Sri Lanka and 6.0% (5.0–6.0) in Pakistan to 16.0% (10.0–24.0) in India, 25.0% (6.0–52.0) in Nepal, and 25.0% (24.0–25.0) in Bangladesh. Similarly, the pooled prevalence of anxiety varied between 3.0% (2.0–3.0) in Afghanistan, 4.0% (3.0–4.0) in Pakistan and 6.0% (2.0–14.0) in India, to 19.0% (16.0–23.0) in Nepal, 21.0% (20.0–22.0) in Bangladesh, and 65.0% (64.0–66.0) in Sri Lanka. The pooled values for both conditions also varied markedly according to whether (and which) diagnostic or screening tools were used to ascertain the presence of depression and/or anxiety. For depression, the pooled prevalence from estimates based on diagnostic tools (e.g., Composite International Diagnostic Interview (CIDI) and Mini International Neuro-psychiatric Interview (MINI)) was 5.0% (3.0–6.0), whereas it was 27.0% (13.0–44.0) based on screening measures. Similarly, the pooled prevalence for anxiety from estimates based on diagnostic tools was 1.0% (0.0–3.0), whereas it was 26.0% (19.0–34.0) based on screening measures. Funnel plot asymmetry was observed and Egger’s test for meta-analysis of depression was statistically significant indicating publication bias. Forest plots for subgroup analyses and funnel plots can be found in Supplementary Appendix 9. Discussion This umbrella review has identified many reviews covering a range of mental disorders in SA, with the majority focusing on the prevalence of CMDs among different population groups. Our findings suggest a high prevalence of these conditions in the region, with greater burden among specific population groups, including perinatal women, older people, people with chronic physical illnesses, refugees, and other vulnerable groups. More than 20 reviews were identified on the prevalence of CMDs during COVID-19 and suggest a high burden of mental disorders among healthcare workers, teachers, and students in SA during the pandemic. In common with Hossain et al. (2020) we found that most studies were from India, while evidence from Afghanistan, Bhutan, and Maldives was particularly limited. The advantages and novelty of this review are in providing a more complete and updated picture of the prevalence of mental disorders in the region. But despite the broader inclusion criteria and the updated searches, we found no reviews with pooled estimates of prevalence for many conditions, including severe mental disorders such as schizophrenia and psychotic disorders, behavioural syndromes, personality disorders, or intellectual disabilities. Reviews without meta-analyses for these conditions were also limited. Further, most reviews scored ‘low’ or ‘critically low’ on quality assessment, with very few assessed as providing an accurate and comprehensive summary of available studies on the topic. Our meta-analysis of primary studies provides pooled estimates for the prevalence of depression and anxiety in the general adult population in SA. We had originally planned to use a 2001 cut-off for the primary studies, set to correspond with the World Health Report on Mental Health (World Health Organization, 2001), but revised this to post-2009 studies, to keep in line with the search period followed by one of the reviews from which we harvested primary studies (Naveed et al., 2020). Similarly, whilst our protocol mentioned meta-analyses for all mental disorders, we limited this step to reviews on CMDs, given these conditions were the focus of the bulk of identified reviews. Both the reviews from which we harvested primary studies had also previously reported pooled estimates for these conditions in SA, but one included studies in all adult populations, including higher-risk perinatal women and older people (Naveed et al., 2020), while the other was limited to studies in Afghanistan and Pakistan (Zuberi et al., 2021). The inclusion of populations with greater disease burden in the former likely explained its higher prevalence compared to our estimates for both depression (26.4% vs. 16.0%) and anxiety (25.8% vs. 12.0%). With regard to the latter review, while reported country-specific pooled estimates are comparable to ours for Pakistan, its estimates are considerably higher for Afghanistan for both conditions (33.0% vs. 5.0% for depression and 25.0% vs. 3.0% for anxiety). This difference may be explained by the inclusion of two studies reporting high prevalence, which were excluded in our review on the basis of publication date (Scholte et al., 2004; Mufti et al., 2005). On the other hand, our searches identified results from a recent national survey on depression and anxiety disorders in Afghanistan, which we included in our meta-analyses (Kovess-Masfety et al., 2021), while the addition of the excluded primary studies from Afghanistan and Pakistan (Nisar et al., 2004) does not considerably change the region-specific pooled estimates for depression or anxiety (Supplementary Appendix 9). In addition to mental disorders, our umbrella review included 23 reviews on suicide and intentional self-harm, including one review with meta-analysis among adults in SA, which reported a 6.4% pooled prevalence of suicidal behaviours (Naveed et al., 2020). Other reviews found adult suicide rates ranging from 0.43 to 331.0 per 100,000 population, which varied greatly across countries in the region, and in some cases are likely to be gross underestimations of actual rates (Jordans et al., 2014). An even higher prevalence of suicidal behaviours was found among specific population groups, including perinatal women (Fuhr et al., 2014; Amiri and Behnezhad, 2021), people with HIV/AIDS (Collins et al., 2006; Das and Leibowitz, 2011), female sex workers (Somrongthong et al., 2019) and tribal populations (Devarapalli et al., 2020). Three reviews on suicidal behaviours among children and adolescents were identified, all from India (Aggarwal and Berk, 2015; Aggarwal et al., 2017; Ganesan et al., 2020). Further, we found three reviews among suicide and self-harm populations, which reported a high prevalence of mental disorders, particularly depressive disorders (Cho et al., 2016; Ahmed et al., 2017; Knipe et al., 2019). Our searches identified three reports based on the Global Burden of Disease studies, which we excluded on the basis of study design (Baxter et al., 2016; Liu et al., 2020; Sagar et al., 2020), and because analyses were either limited to just India or estimated annual percentage change in the burden of depression across the region, not directly comparable to the results of our analyses. Similarly, three reviews (Reddy and Chandrashekar, 1998; Ganguli, 2000; Arora and Aeri, 2019) included in the Hossain et al. (2020) umbrella review did not meet our eligibility criteria on study design, but those topics were covered in other included reviews. Our review includes all other reviews they included, but by going beyond geographically limited reviews and summarising the evidence from multi-country reviews that included at least one South Asian country, we have identified many more reviews, providing a more complete picture of the evidence regarding the prevalence of mental disorders in the region. Diverse terms were used to describe the reviews that were included (systematic, scoping, narrative, etc.), but we screened for studies that met our criteria to be considered systematic reviews, and thereby ensured consistency in our inclusions (Haddaway et al., 2022). In addition, our meta-analyses of primary studies on depression and anxiety provide important new information on the prevalence of these conditions among the general adult population in the region. Some key limitations of the research should be acknowledged. First, our approach for identifying primary studies was through harvesting studies from included reviews and forward citation screening, rather than a systematic search and screening of databases. This may have missed studies and introduced a selection bias, but our pre-defined strategy on having a registered protocol likely protected against this. In addition, there are possibilities of publication bias, which our funnel plots suggested were likely. Our meta-analyses also found high heterogeneity, which could be explained to some extent by differences between countries and assessment tool used, demonstrated by subgroup analyses. The finding that studies using screening tools report higher prevalence than those using diagnostic interviews has been previously reported, which may have overestimated the prevalence of mental disorders (Zuberi et al., 2021). In the methodological literature on clinical trials, developing and adopting ‘core outcome sets’ has been advocated to address the heterogeneity that precludes meaningful synthesis of evidence across studies. Core outcomes sets mandate the inclusion of key outcomes to be measured in all trials of interventions for particular conditions and may also define the tools to be used to measure them (Chiarotto et al., 2017). A similar agreed set of defined measures for observational studies of various mental ill health conditions may be a way forward for better synthesis. Next, although the majority of primary studies received overall high ratings, few were nationally representative surveys of the general adult population. Nonetheless, there were primary studies from most countries in the region, apart from Bhutan and Maldives. In contrast to the quality of primary studies in our meta-analyses, our narrative synthesis is largely based on reviews that scored ‘low’ or ‘critically low’. We therefore limited our presentation of prevalence estimates solely to the meta-analytical reviews, while the overall narrative summary provides a broader mapping of identified evidence from all reviews by type of review and mental disorder. Finally, there is the possibility that our umbrella review may have missed some relevant reviews on mental disorders in SA, but we searched a large number of (including region-specific) databases and reviewed the literature as comprehensively as possible. Overall, the findings of our research show a high burden of mental disorders among the general-adult population in SA, with even higher prevalence among specific population subgroups. These findings are also supported by reviews published since our searches were carried out (Manna et al., 2022; Palfreyman and Gazeley, 2022; Al-Mamun et al., 2023; Javan Biparva et al., 2023). Our results highlight an urgent need for countries in SA to formulate and implement both clinical and policy measures for the prevention and early treatment of mental disorders and intentional self-harm. The mapping of evidence according to the type of review and mental disorder (Supplementary Appendix 8) shows that population-level prevalence estimates are generally lacking beyond CMDs, including for schizophrenia and psychotic disorders, behavioural syndromes, personality disorders, and intellectual disabilities. These identified gaps are supported by other recent reviews (Russell et al., 2022; Bastien et al., 2023), and should be a focus of future research, along with the strengthening of epidemiological surveillance systems to better capture morbidity, mortality, and economic burden of all mental disorders and intentional self-harm in the region. Supporting information Vidyasagaran et al. supplementary material Vidyasagaran et al. supplementary material To, The Editorial Team Global Mental Health 17 April 2023 Subject: A systematic umbrella review and meta-analysis on ‘Prevalence of mental disorders in South Asia’ for your consideration Dear Editorial Team, We hereby submit our article titled “Prevalence of mental disorders in South Asia: A systematic review of reviews” to Global Mental Health for your consideration. To our knowledge, this study provides the most comprehensive and up-to-date estimates for the prevalence of mental disorders and intentional self-harm in South Asia. Through extensive searching and rigorous screening processes, we have identified a large number of systematic reviews reporting the prevalence of mental disorders and/or intentional self-harm in South Asian countries. We have followed the recommended best practices for conducting and reporting our research, and the manuscript is drafted following GMH’s formatting guidelines. In addition to narratively synthesising findings from the reviews themselves, we identified primary studies of common mental disorders among adults from a subset of selected reviews and their forward citations and pooled them using random-effect models. Our findings highlight the need for South Asian countries to formulate and implement both clinical and policy measures for the prevention and early treatment of these conditions within the region. This research was funded by the UK National Institute for Health Research (NIHR) – Grant 17/63/130 NIHR Global Health Research Group: Improving Outcomes in Mental and Physical Multi-morbidity and Developing Research Capacity (IMPACT) in South Asia at the University of York. Please let us know if any further information is required. With many thanks for your consideration, Yours sincerely, Aishwarya (on behalf of the review team) I appreciate the efforts of the authors to summarize the evidence on the prevalence of mental disorders in South Asia. This systematic review of reviews provides an updated evidence summary that extends both the umbrella review (Hossain et al., 2020) and the meta-analytic review (Naveed et al., 2020) on the same topic. The added value of this review is that offers a methodological integration of these past reviews, through an overview of reviews and also through a meta-analysis of prevalence from empirical works. However, there is a critical concern regarding the conceptualization of this work. This review of the reviews has adhered to the JBI guidelines (Aromataris, 2015), which clearly stated two fundamental aspects of umbrella review. One, umbrella reviews should include reviews with the same/similar scope- to prevent a mismatch of evidence in context. For example, an umbrella review of an epidemiologic phenomenon in a given population should include reviews that focused on that population only. The inclusion of any review that includes one or a few studies from that population but may also include studies from other geographies or populations can affect the generalizability of evidence if summarized through an umbrella review. This is critical for umbrella review because in this methodology the “level of synthesis” is “reviews only” – therefore, any review that did not explicitly focus on the population of interest can contaminate the overall evidence presented in the umbrella review. I appreciate the idea of a meta-analytic review complementing the evidence base of the umbrella review - it is acceptable that the authors may include effect sizes from studies in mixed populations reviews as long as a primary study was conducted in one of the South Asian countries. However, those mixed reviews should not be included in the narrative umbrella review summary or in any pooling approach in the meta-analytic review. Their only possible contribution can be informing the existence of one/more studies/effect sizes within that review. In that case, the respective review should not be included in the last box of the flow chart, rather, it should provide/inform additional article(s) that would enrich the meta-analysis only. This approach, if done carefully, can preserve the value of the meta-analysis as well as provide a clean and intensive overview in the umbrella review. This is useful from a reader’s perspective as well. A potential reader or user of the review won’t benefit from the summary of the characteristics of “reviews” that may include a significant proportion of studies conducted outside of South Asia. If the authors aim to keep those studies, then the study title should not include South Asia only, which will jeopardize the authors' efforts and the paper’s appeal. Rather, summarizing South Asia-focused papers, plus pooling the prevalence from all primary studies in existing meta-analytic reviews as well as “mixed populations” reviews, can offer an acceptable body of evidence that may inform more accurate insights on mental health in South Asian populations. I’d recommend reforming the results of the paper and making it consistent with the JBI approach addressing the concerns above. That may reduce the count of reviews in the narrative synthesis, but the value of mixed reviews will be preserved if they can offer studies/effects to the meta-analysis. The inclusion of any reviews with fewer South Asian studies would be enormously problematic, as stated above. The rest of the paper looks excellent; perhaps adding some insights for public mental health research and policymaking- based on the summarized evidence- could strengthen the discussion. Lastly, I congratulate the authors for their contributions to the critical topic, and I hope they’ll revisit their work to make it better from a methodological and practical perspective. Reference Aromataris, E., Fernandez, R., Godfrey, C. M., Holly, C., Khalil, H., & Tungpunkom, P. (2015). Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. JBI Evidence Implementation, 13(3), 132-140. Hossain, M. M., Purohit, N., Sultana, A., Ma, P., McKyer, E. L. J., & Ahmed, H. U. (2020). Prevalence of mental disorders in South Asia: An umbrella review of systematic reviews and meta-analyses. Asian journal of psychiatry, 51, 102041. Naveed, S., Waqas, A., Chaudhary, A. M. D., Kumar, S., Abbas, N., Amin, R., … & Saleem, S. (2020). Prevalence of common mental disorders in South Asia: a systematic review and meta-regression analysis. Frontiers in psychiatry, 11, 573150. Dear Authors, This is a competent, thorough and well-rationalised review - and was a pleasure to work through. While I’m conscious some new relevant publications (including systematic reviews for the South Asia region) have come out since your search date in 2021, this is a useful contemporary snapshot of what is available. Given the classic and persistent challenge of heterogeneity in study tools and design which makes meta-analyses so difficult to do, do signpost to the Appendix table 7 indicating which instrument(s) were used in each primary study. This could then be part of brief, but more explicit reflection on what could be done to move this issue forward around heterogeneity, particularly for under-studied issues (i.e., seemingly all those beyond depression and anxiety). Stressing the lack of evidence beyond CMDs, the need to move beyond prevalence studies, and heterogeneity of research design would be welcome and Appendix 7 could be informative for those looking to tackle some of these chronic challenges. Best Thank you for submitting your review to Global Mental Health. We have received responses from two reviewers who both noted several strengths of this review, specifically how it builds on prior reviews on this topic. The two reviewers have provided some suggestions regarding the presentation of the results, the methodology, and have requested additional reflections on the measurement considerations. We hope you will consider revising your article based on these suggestions. No accompanying comment. Dear reviewers and editors Thank you for the opportunity to revise our manuscript as per the constructive editorial and peer-review feedback. We have carefully considered all the feedback received and made appropriate revisions to our manuscript and supplementary material. We trust that these revisions are to your satisfaction. Please do not hesitate to contact us if you require any further information or clarification. Yours sincerely, Dr Aishwarya Vidyasaragan (on behalf of all co-authors) Dear authors, The review already displayed competence and thorough thought and attention to detail in round 1. Feedback appears to have been addressed with greater clarity in a number of spots across the manuscript. There are some 2022/23 systematic reviews inclusive of South Asian country data to my knowledge which would be relevant here (too late of course for inclusion in the analysis itself but could possibly be pulled in for discussion as some takeaways reinforce your recommendations at least for sub-groups, e.g., adolescents and perinatal women). See Gazeley and Palfreyman 2022 for example; there may be forward citations there. Appendix 8 and the addition of core outcome sets are both constructive; the lean towards talking in terms of transdiagnostic criteria and tools is also relevant here. Tiny proofreading - check line 293: ‘… we searched a large number OF (including region-specific) databases…’. The word ‘of’ is missing. I have no additional critique warranting meaningful changes. Well done. The reviewer expressed appreciation for the significant improvements made to the paper based on their feedback. However, they have a couple of minor points for your attention. No accompanying comment. Dear Editors, We are grateful for the opportunity to revise our paper in light of the reviewers’ helpful feedback. We trust that these revisions are to your satisfaction. Please do not hesitate to contact us if you require any further information or clarification. Yours sincerely, Dr Aishwarya Vidyasaragan (on behalf of all co-authors) All comments previously shared have been sufficiently addressed. I have no further inputs. Congratulations to the authors on a thorough and competent review. No accompanying comment. No accompanying comment.